(Press-News.org)
A new biotech company forged through an Australian and Danish partnership will accelerate treatments for children and adults with heart disease. Harnessing cellular therapies, the company aims to conduct human clinical trials within three to five years.
Ibnova Therapeutics, launched today, has emerged from world-first, collaborative research by Murdoch Children’s Research Institute (MCRI) in Melbourne and QIMR Berghofer in Brisbane. Within MCRI, this work is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), which is headquartered in Copenhagen, and has research nodes in the University of Copenhagen, Leiden University Medical Center in the Netherlands and MCRI.
Based in Denmark, Ibnova Therapeutics is backed by the BioInnovation Institute (BII) Venture Lab program and the Novo Nordisk Foundation Cellerator, initiatives designed to allow researchers to transform their scientific breakthroughs into viable therapies.
Ibnova Therapeutics will advance the development and commercialisation of stem cell-based treatments for heart failure pioneered by MCRI Professor Enzo Porrello and QIMR Berghofer Professor James Hudson.
The research team, including cardiac surgeons and cardiologists from Melbourne’s The Royal Children’s Hospital and The Alfred Hospital, has shown that lab-grown human heart muscle can restore heart function after a heart attack. The team has also proved this approach is safe and effective in animal models.
The foundational intellectual property underpinning Ibnova Therapeutics was made possible through significant support from reNEW, which enabled MCRI researchers to advance these early‑stage discoveries. This stem cell research has also received support over a decade from the Australian Research Council, the Medical Research Future Fund and the National Health and Medical Research Council.
Heart failure, a life‑threatening condition where the heart struggles to pump enough blood around the body, affects more than 60 million people globally. While a heart transplant is the only viable treatment for end‑stage heart failure, the severe shortage of donor organs presents a significant and ongoing challenge.
Ibnova Therapeutics Executive Director, Chief Scientific Officer and Co-Founder Andrew Laskary said the company’s mission was to bring cellular therapies to heart failure patients as quickly and safely as possible.
“With Ibnova, we can now bridge the hardest gap in medicine by turning breakthrough biology into a clinical-ready therapy,” he said. “By combining Australia’s discovery engine with Denmark’s translational ecosystem, we’re building a focused path to first-in-human trials by aligning manufacturing readiness, regulatory strategy and clinical partnerships. We’re grateful for the opportunity to launch from the BioInnovation Institute in partnership with the Novo Nordisk Foundation Cellerator. This work reflects the interdisciplinary effort required to translate foundational research into therapies that are ready for patients.”
The BII Venture Lab will provide early-stage funding, business development and a base as the company scales up. The Novo Nordisk Foundation Cellerator will provide the expertise to manufacture the engineered heart tissue to meet therapeutic requirements.
Professor Porrello, also an Ibnova Therapeutics Co-Founder, said the company highlighted the need for early and sustained investment in transformative technologies and the important role of industry partnerships to enable advanced manufacturing and clinical trials.
“We are incredibly excited to announce the launch of Ibnova Therapeutics and move our stem cell technology towards clinical trials,” he said. “This would not have been possible without the support of reNEW and our Novo Nordisk Foundation ecosystem partners in Denmark including the Cellerator and the BioInnovation Institute.”
Professor Hudson, also an Ibnova Therapeutics Co-Founder, said “The technology was developed on the backing of over a decade of research into creating multicellular bioengineered tissues. The mechanistic science underpinning this technology is pivotal to its substantial improvement in heart function.”
MCRI Chief Scientist and reNEW CEO Professor Melissa Little said, “The mission of reNEW is to move the very best stem cell science through to the development of new therapies. The formation of Ibnova Therapeutics from the research in the Australian node is precisely what we aim to achieve.”
Available for interview:
Professor Enzo Porrello, MCRI Director of Stem Cell Medicine, reNEW Melbourne Node Director and Ibnova Co-Founder
Professor Melissa Little, MCRI Chief Scientist and reNEW CEO
Andrew Laskary, Ibnova Therapeutics Executive Director, CSO and Co-Founder
Professor James Hudson, QIMR Berghofer, Cardiac Bioengineering Senior Group Leader and Ibnova Therapeutics Co-Founder
END
The faba bean is an ancient crop. It is particularly valuable because it is high in protein, and can convert nitrogen from the air into a form that can be used by plants in the soil. This makes it a sustainable alternative to soy, particularly in Europe. However, many varieties are not winter-hardy. In cold regions, they do not survive frost.
Firstly, the research team succeeded in significantly improving the reference genome of the faba bean. Various methods, such as optical mapping, were used to assemble the genome’s individual sections more precisely. “Our new ...
Can smartphones or smartwatches help detect early signs of neurological or mental illness? Researchers at the University of Geneva (UNIGE) monitored a group of participants wearing connected devices, and used artificial intelligence to analyse data such as heart rate, physical activity, sleep and air pollution. Their findings show that connected devices can accurately predict emotional and cognitive fluctuations, opening new avenues for the early detection of changes in brain health. The study has been published in npj Digital Medicine.
Brain health, encompassing both cognitive and emotional functions, is one of the major public health challenges of the ...
Many of the key proteins for modern medicine and science are poorly soluble. These include numerous signalling proteins and protein hormones, as well as all of the receptors anchored in the cell membranes, which are targeted by around 60 percent of the active ingredients currently used in medicines. If the concentration of these proteins exceeds a certain threshold, they clump together and lose their function.
This clumping makes it impossible to produce these molecules synthetically in the lab. As protein production with specialised synthesis robots always requires multiple fragments to be coupled into a complete protein, ...
In the evolutionary history of life, the ability of a cell to separate its inner world from the external environment was an important turning point. The so-called plasma membrane lets cells control what gets in and out and allows them to communicate and cooperate with one another, creating the conditions for complex, multicellular life.
This barrier is fragile. Every day, mechanical stress, environmental changes, and bacterial toxins threaten to puncture the membrane, and if the wounds aren’t sealed and healed quickly, the cell dies. Despite its importance to the survival of our cells, the processes of plasma membrane ...
CAMBRIDGE, Cambridgeshire, UNITED KINGDOM, 10 March 2026 — A comprehensive invited review published today in Brain Medicine confronts one of the most persistent paradoxes in modern medicine: psychiatry remains the only major clinical discipline that diagnoses complex illness primarily through conversation and symptom checklists, while fields such as oncology and cardiology long ago embraced laboratory markers, imaging, and molecular profiling. The review, authored by Dr. Jakub Tomasik, Jihan K. Zaki, and Professor Sabine Bahn at the Cambridge Centre for Neuropsychiatric Research, University of Cambridge, synthesizes emerging research across conceptual frameworks, ...
OSLO, Eastern Norway, NORWAY, 10 March 2026 — An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide association studies, whole-exome sequencing projects, and advanced statistical modeling to illuminate the polygenic architecture that underpins these heterogeneous neurological disorders. The synthesis, led by Dr. Olav B. Smeland of the Centre for Precision Psychiatry at Oslo University Hospital and the University of Oslo, draws a detailed portrait ...
NEW YORK, New York, UNITED STATES, 10 March 2026 — The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the treatment of obesity and diabetes so thoroughly that the word "blockbuster" barely covers it. And yet for all the billions of dollars spent, for all the prescriptions written, a fundamental question has lingered like a low hum beneath the clinical noise: where, precisely, does GLP-1 live inside the brain, ...
CORK, Munster, IRELAND, 10 March 2026 — Something happens when a rat starts running. Not just the obvious things, the faster heart, the warming muscles, the rhythmic percussion of paws against the wheel. Something quieter. Something that begins in the coiled darkness of the gut and travels, through blood and biochemistry, all the way to the hippocampus, that seahorse-shaped sliver of tissue where memories form and moods take root. A new study published in Brain Medicine, a Genomic Press journal, ...
Scientists have successfully reconstructed videos purely from the brain activity of mice, showing what the mice were seeing, in a new study led by University College London (UCL) researchers.
The findings, published in eLife, could help shed light on the intricate workings of how the brain processes visual information and open new avenues for exploring how different species perceive the world.
Over recent years, there has been a growing interest in understanding exactly how the human brain interprets ...
A new study led by researchers at the Earth-Life Science Institute (ELSI) at Institute of Science Tokyo challenges a long-standing assumption about Earth's most extreme ice ages. Using numerical geochemical models, the team showed that chemical weathering may have continued beneath thick continental ice sheets during the snowball Earth event, consuming atmospheric carbon dioxide (CO₂) and potentially prolonging the global glaciation. The findings provide a new explanation for the unusually long duration of some ancient global glaciations.
"Our results demonstrate that subglacial weathering represents a previously unrecognised feedback mechanism that could account ...
